MNTL TEMA NEUROSCIENCE AND MENTAL HEALTH ETF
- 25.938
- +0.176+0.68%
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Capricor Stock Rallies 20% on DMD Data Presentation Update
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Neurocrine Biosciences Analyst Ratings
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Biogen Analyst Ratings
Market Whales and Their Recent Bets on REGN Options
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Eli Lilly Analyst Ratings
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
Larimar Started at Outperform by Wedbush on FA Drug Candidate
Dianthus Started at Outperform by Oppenheimer on DNTH103 Opportunity
Looking Into Biogen's Recent Short Interest
BofA's Top 10 Growth Stocks for October
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why